The KeyPath test not only identifies a Staphylococcus aureus infection but also determines whether the strain is methicillin resistant (MRSA) or methicillin susceptible (MSSA) providing the physician to determine an effective course of treatment.
The test, developed using MicroPhage’s proprietary Bacteriophage Amplification Technology (BAT) platform, meets Clinical and Laboratory Standards Institute (CLSI) and FDA criteria.
MicroPhage CSO Drew Smith said the BAT platform provides a phenotypic result that directly assesses the organism’s response to an antibiotic.
"The platform can be extended to a broad range of bacterial pathogens and sample types thus enabling development of clinically useful susceptibility tests and test panels," Smith said.
The MicroPhage product pipeline includes rapid single-pathogen and multi-pathogen diagnostic tests for simultaneous detection and determination of antibiotic susceptibility.
The KeyPath test has already achieved CE marking and commercialization efforts are under way in Europe.
